Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 22;6(5):309–316. doi: 10.1002/jgh3.12737

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Osaka International Cancer Institute. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

(a) Changes in serum hepatitis C virus (HCV) RNA level during ICI treatment. One patient who did not have post‐treatment data due to poor prognosis was excluded. (b) Case presentation in a chronic hepatitis C patient whose serum HCV RNA levels declined during the carboplatin (CBDCA), nab‐paclitaxel [PTX], and pembrolizumab therapy accompanied by grade 2 liver injury. Day 1 was defined as the day of the first administration of CBDCA, nab‐PTX, and pembrolizumab. (), HCV RNA; (), alanine aminotransferase (ALT).

Inline graphic — (a) Changes in serum hepatitis C virus (HCV) RNA level during ICI treatment. One patient who did not have post‐treatment data due to poor prognosis was excluded. (b) Case presentation in a chronic hepatitis C patient whose serum HCV RNA levels declined during the carboplatin (CBDCA), nab‐paclitaxel [PTX], and pembrolizumab therapy accompanied by grade 2 liver injury. Day 1 was defined as the day of the first administration of CBDCA, nab‐PTX, and pembrolizumab. (), HCV RNA; (), alanine aminotransferase (ALT).